RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

RMD Open publishes high-quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism, and connective tissue diseases, including osteoporosis, spine issues, and rehabilitation. The journal considers clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that contribute to the literature.

RMD Open 期刊发表高质量的同行评审原创研究，涵盖肌肉骨骼疾病、风湿病和结缔组织疾病的各个方面，包括骨质疏松、脊柱及康复。我们接受临床和流行病学研究、基础和转化医学、引人注目的临床案例，以及能够丰富文献的小型研究。

RMD Open

It is known that metabolic shifts and tissue remodelling precede the development of visible inflammation and structural organ damage in inflammatory rheumatic diseases such as the inflammatory arthritides. As such, visualising and measuring metabolic tissue activity could be useful to identify biomarkers of disease activity already in a very early phase. Recent advances in imaging have led to the development of so-called ‘metabolic imaging’ tools that can detect these changes in metabolism in an increasingly accurate manner and non-invasively. Nuclear imaging techniques such as 18 F-D-glucose and fibroblast activation protein inhibitor-labelled positron emission tomography are increasingly used and have yielded impressing results in the visualisation (including whole-body staging) of inflammatory changes in both early and established arthritis. Furthermore, optical imaging-based bedside techniques such as multispectral optoacoustic tomography and fluorescence optical imaging are advancing our understanding of arthritis by identifying intra-articular metabolic changes that correlate with the onset of inflammation with high precision and without the need of ionising radiation. Metabolic imaging holds great potential for improving the management of patients with inflammatory arthritis by contributing to early disease interception and improving diagnostic accuracy, thereby paving the way for a more personalised approach to therapy strategies including preventive strategies. In this narrative review, we discuss state-of-the-art metabolic imaging methods used in the assessment of arthritis and inflammation, and we advocate for more extensive research endeavours to elucidate their full field of application in rheumatology.

Rita Noversa de Sousa

Koray Tascilar

Giulia Corte

Armin Atzinger

Ioanna Minopoulou

Sarah Ohrndorf

Maximilian Waldner

Christian Schmidkonz

Torsten Kuwert

Ferdinand Knieling

Arnd Kleyer

Andreas Ramming

Georg Schett

David Simon

Filippo Fagni

Metabolic and molecular imaging in inflammatory arthritis

炎症性关节炎的代谢与分子影像学

We aimed to assess the prevalence of clonal haematopoiesis (CH) in patients with giant cell arteritis (GCA) compared with controls and individuals with other autoimmune diseases (AIDs) and to identify high-risk clinical/genetic profiles that could influence disease outcomes.

Alexis F Guedon

Asmaa Ouafdi

Nabil Belfeki

Azeddine Dellal

Nouha Ghriss

Marc Scheen

Fadi Haidar

Olivier Espitia

Jean-Yves Scoazec

Olivier Fain

Christophe Marzac

Olivier Hermine

Eric Solary

Julien Rossignol

Arsène Mekinian

Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis

TET2突变型巨细胞动脉炎患者中更高风险特征：一项聚类分析

It is known that 25%–30% of individuals with cutaneous psoriasis (PsC) will develop psoriatic arthritis (PsA). To date, the reasons for the development of PsA in individuals with PsC have not been identified. Furthermore, there are considerable delays in the diagnosis and treatment of PsA, which lead to joint and bone deformation and chronic pain. It is therefore important to develop more precise diagnostic and screening tools. In this narrative review of the literature, clinical risk factors and novel molecular biomarkers (genetic markers, blood and inflammatory markers, lipid, metabolite and protein biomarkers) have been evaluated. The review included 38 publications that were reported between May 2020 and May 2024. Similar to previous reviews, nail involvement was one of the strongest clinical risk factors for the development of PsA, while molecular biomarkers did not provide a clear and robust differentiation between PsC and PsA groups. The seemingly poor performance of molecular markers may be largely attributed to small study populations and heterogeneity in study designs. Data and sample sharing in large consortia such as HIPPOCRATES (Health initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States) could help to overcome the limitations of small studies and enable the development of more robust diagnostic and screening tools for PsA.

Teresa Grohmann

Arani Vivekanantham

Laura C Coates

Stephen Pennington

Oliver FitzGerald

Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis: a narrative review of the literature

临床、遗传和多组学标志物可能支持银屑病患者中银屑病关节炎发展的识别：文献叙述性综述

Secondary lymphoid organs such as lymph nodes (LNs) are the home of peripheral tolerance mechanisms which control autoreactive T cells and prevent immune responses to self-antigen. In systemic autoimmunity, there is a clear failure of these peripheral tolerance mechanisms that leads to chronic inflammation and tissue destruction, highlighting the role for LNs as possible gatekeepers of autoimmunity. In recent years there has been a shift in research focus towards tissue sites in autoimmune diseases ranging from type 1 diabetes to rheumatoid arthritis in an effort to better characterise pathogenesis and guide diagnostic and therapeutic decisions. Although this has yielded great insight, it fails to tackle the initial break in tolerance that initiates disease progression which is most likely originating in peripheral LNs. In the majority of autoimmune diseases a preclinical phase is recognised. This is characterised by the presence of autoantibodies, which is indicative of a break in immune tolerance, and the absence of clinically apparent inflammation or tissue destruction. This review explores how our current knowledge of LNs in the preclinical and established phases of autoimmune diseases provides insight into possibly shared pathological mechanisms that drive disease progression and highlight the gaps in our knowledge that may help uncover new therapeutic avenues for intervention and prevention.

Aoife M O'Byrne

Lisa G M van Baarsen

Lymph nodes as gatekeepers of autoimmune diseases

淋巴结作为自身免疫性疾病的守门人

Objectives To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with psoriatic arthritis (PsA) and inadequate response to tumour necrosis factor inhibitors (TNFi-IR) from the phase 3b COSMOS trial. Subgroups were defined by baseline demographics, disease characteristics and prior/ongoing therapies. Methods Patients with active PsA (tender joint count (TJC) and swollen joint count (SJC) both ≥3) and TNFi-IR were randomised 2:1 to receive guselkumab 100 mg at week 0, week 4, then every 8 weeks through week 44 or to placebo with cross-over to guselkumab 100 mg at week 16 (early escape) or week 24 (planned). Guselkumab effect on joints (American College of Rheumatology (ACR) 20/50/70, enthesitis, dactylitis), skin (Psoriasis Area and Severity Index 90/100, Investigator’s Global Assessment 0/1), patient-reported outcomes (PROs) (Functional Assessment of Chronic Illness Therapy–Fatigue, Health Assessment Questionnaire–Disability Index) and composite outcome measures (PsA Disease Activity Score low disease activity, minimal disease activity) were evaluated by baseline patient age, sex, body mass index, SJC, TJC, PsA duration, %body surface area, C reactive protein, pain Visual Analogue Scale, number of prior TNFi and discontinuation reason, and conventional synthetic disease-modifying antirheumatic drug status. Results are descriptive only. Results Baseline characteristics were similar between guselkumab (n=189) and placebo (n=96) groups. The benefit of guselkumab over placebo in achieving ACR 20 (primary endpoint; 50% vs 28%) and ACR 50 (23% vs 8%) response at week 24 was observed within all subgroups. Furthermore, response rates in the guselkumab group increased between week 24 and week 48 within almost all subgroups. Similar response patterns at week 24 and through week 48 were observed across various clinical outcomes. Conclusions Guselkumab every 8 weeks led to consistent improvements through week 24 in joint, skin, PRO and composite outcomes versus placebo across diverse baseline-defined subgroups of TNFi-IR patients with PsA. Response rates increased or were durable through week 48 within most subgroups.

Iain B McInnes

Philipp Sewerin

Mohamed Sharaf

Michela Efficace

Frédéric Lavie

Miriam Zimmermann

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

无论活动性银屑病关节炎患者基线特征如何，对古塞库单抗的持续应答及对TNF抑制剂反应不足的结果：来自3b期COSMOS临床试验的结果

Systemic sclerosis (SSc) is an autoimmune connective disease characterised by excessive extracellular matrix deposition and widespread skin and internal organ fibrosis including various cardiac manifestations. Heart involvement is one of the leading causes of death among patients with SSc. In this study, we aimed to assess the effect of various vasodilator treatments.

Alexis F Guédon

Fabrice Carrat

Luc Mouthon

David Launay

Benjamin Chaigne

Grégory Pugnet

Jean-Christophe Lega

Arnaud Hot

Vincent Cottin

Christian Agard

Yannick Allanore

Anne Laure Fauchais

Alain Lescoat

Robin Dhote

Thomas Papo

Emmanuel Chatelus

Bernard Bonnotte

Jean-Emmanuel Kahn

Elisabeth Diot

Achille Aouba

Nadine Magy-Bertrand

Viviane Queyrel

Alain Le Quellec

Pierre Kieffer

Zahir Amoura

Brigitte Granel

Jean Baptiste Gaultier

Marie-Hélène Balquet

Denis Wahl

Olivier Lidove

Ariel Cohen

Eric Hachulla

Sébastien Rivière

Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis

血管扩张药物与系统性硬化症心脏相关结局的探索性分析

Abbreviation	RMD Open
Journal Impact	4.93
Quartiles(Global)	RHEUMATOLOGY(Q1)

ISSN	2056-5933
h-index	61

Publication Information	Publisher: BMJ Publishing Group，Publishing cycle: ，Journal Type: journal，Open Access Journals: Yes
Basic data	Year of publication: 2015，Proportion of original research papers: 87.91%，Self Citation Rate:5.90%， Gold OA Rate: 99.51%
Journal Fees	$Details
Average review cycle	网友分享经验：14 Weeks

RMD Open

Journal Citation Format

A journal article with 1 author

A journal article with 2 authors

A journal article with 3 authors

A journal article with 5 or more authors

Books Citation Format

Thesis Citation Format

Web sites Citation Format

Patent Citation Format

Staying up late manually editing references? ivySCI automatically matches journals and helps you generate references with a single click.

Share Submission Experience

Metabolic and molecular imaging in inflammatory arthritis

Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis

Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis: a narrative review of the literature

Lymph nodes as gatekeepers of autoimmune diseases

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis

Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis: a narrative review of the literature

Lymph nodes as gatekeepers of autoimmune diseases

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis